India revokes patent on Merck & Co's asthma drug on Cipla complaint
- India's future cannot exist without the future of Kashmir: Rajnath Singh
- Will appoint nodal officer to help Kashmiri youth across the country: Rajnath Singh in Srinagar
- Dec 16 Delhi gangrape case: Convict attempts suicide inside Tihar Jail, rushed to hospital
- Earthquake in Italy kills 247, toll may rise as rescuers continue hunt for survivors
- Rahul Gandhi twisting statement, must show generosity, apologise: RSS
Indian Patents Office has revoked a patent for an asthma drug held by US-based Merck & Co following a challenge from domestic pharma firm Cipla.
In an order, Assistant Controller of Patents & Designs T V Madhusudhan revoked the patent on the ground that it lacked invention.
"The sole process claim also in its entirety is not inventive as the said claim does not describe any inventive feature," the order said.
"In view of the above conclusion I hereby order that the patent bearing number 246328 is revoked," Madhusudhan said in his order.
Schering Corporation, which was later acquired by Merck & Co, had applied for patent of the asthma drug in February 2004, and the Indian Patents Office had granted the patent in March 2011. Cipla had challenged the patent.
The development is the latest in a series of patent revocations by India's Patent Office.
Last month, the Intellectual Property Appellate Board (IPAB) had turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.
Similarly, it had also revoked Pfizer's patent on cancer drug 'Sutent'. The drug was granted a patent in India in 2007 but Cipla had opposed it the following year.
- Sedition law cannot be used against honest views, expressed peacefully
- India’s dependence on China for medicine ingredients is a matter of concern
- Before Balochistan, India has supported some human rights causes and ignored others
- Olympics brought many smiles — and a little bit of rancour
- Harish Gupta case involves questions about the very nature of governmental decision-making
- Tension between the executive and judiciary could play out in creative, or destructive, ways